ClinicalTrials.gg
RecruitingNCT07740564Updated Oct 15, 2026

Phase III Study of OT202 in Treating Moderate to Severe Dry Eye

A Phase 3 interventional study of OT202 conc 1% and Placebo in Dry Eye, sponsored by Ocumension Therapeutics (Suzhou) Co., Ltd. Recruiting at 49 sites in China. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Ocumension Therapeutics (Suzhou) Co., Ltd · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 15, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
842
Allocation
Randomized
Ages
30 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Dry Eye Syndromes with a site in China — 28 open to participants now, 30 under way, 3 of them phase 3. Dry Eye Syndromes · China.

Planned enrollment
Largest of 83
842 · median 80
Started
2026
with 10 others
Phase 3
10 of 106
3 open now
Primary completion
2029-01
later than 28 of 29 live
Registered
103rd of 106
by date

Among the 106 studies in Dry Eye Syndromes with a site in China, this one has the largest planned enrollment of the 83 interventional ones that give a count, is one of 11 that started in 2026, is one of 10 in phase 3, reaches primary completion later than 28 of the 29 other live ones, and was the 103rd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

28 of the 106 studies in Dry Eye Syndromes with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 30 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Dry Eye Syndromes with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial, enrolling 842 subjects with moderate to severe dry eye, who will be randomized at a 1:1 ratio to receive either 1% OT202 ophthalmic solution or vehicle control. The trial consists of screening, run-in, 8-week double-blind treatment period, and three long-term safety follow-up cohorts (10 weeks, 28 weeks, and 54 weeks), including 342 subjects for the 10-week follow-up, 350 subjects for the 28-week follow-up, and 150 subjects for the 54-week follow-up. Unblinding will be performed after the completion of double-blind treatment for all subjects, who will then receive open-label 1% OT202 ophthalmic solution uniformly. The co-primary efficacy endpoints are the change from baseline in Total Corneal Fluorescein Staining Score (TCSS) and Visual Analog Scale-Eye Dryness Score (VAS-EDS) at Day 56. Pharmacokinetic assessments will be conducted in 60 of the subjects assigned to the 54-weeks long-term safety follow-up. An interim futility analysis will be performed once approximately 30% of subjects complete the treatment period. Analysis of covariance (ANCOVA) will be utilized for efficacy statistical analyses. The primary objective is to evaluate the efficacy and safety of OT202 ophthalmic solution in the treatment of moderate to severe dry eye.

03

Conditions studied

  • Dry Eye

Browse trials for

Keywords

  • Moderate dry eye
  • Severe dry eye
04

Who can participate

Ages eligible
30 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 30 to 75 years of age (inclusive) at the time of signing the ICF, either sex or ethnic group.
  2. With history of dry eye for at least 6 months prior to screening, and history of use or willingness to use eye drops for the treatment of dry eye within 6 months prior to screening.
  3. Binocular BCVA ≥ 0.25 decimals (standard logarithmic visual acuity chart) at Screening and Baseline.
  4. At least one eye (the same eye) meets all the following criteria at screening and baseline:

    • 5 ≤ TCSS ≤ 15, with individual corneal region staining ≤ 3
    • Eye dryness score (EDS) ≥ 40 points in VAS
    • TFBUT ≤ 5 seconds
    • 1 mm/5 min ≤ Schirmer I test (without surface anesthesia) ≤ 10 mm/5 min
  5. Must be able to understand and sign the ICF approved by Independent Ethics Committee (EC).
  6. Willing and able to conduct protocol-required study visits, follow study guidelines, and take study drug as instructed.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously participated in a Phase I or Phase II clinical study of OT202
  2. With or to the study drug (OT202 and ) or diagnostic reagents (fluorescein sodium, lissamine green, etc.).
  3. During the screening period and baseline period, any eye with ocular active inflammation or structural abnormalities that may affect the trial assessment, including but not limited to trichiasis, blepharospasm, blepharitis, meibomitis, severe meibomian gland dysfunction(diagnosed according to the Expert Consensus on the Diagnosis and Treatment of Meibomian Gland Dysfunction in China (2023)), bulbar conjunctival laxity, keratitis, recurrent corneal erosion, allergic conjunctivitis, iritis, anterior chamber inflammation, known retinal detachment, diabetic retinopathy, or history of any progressive retinal disease.
  4. With history of possible or confirmed ocular infection (bacterial, viral, or fungal) or ocular herpes (simple or zoster) in either eye, as determined by the patient's medical history and/or at the screening and baseline examinations.
  5. Those with intraocular pressure (non-contact tonometry) greater than 21 mmHg or less than 8 mmHg or diagnosed with glaucoma at screening and baseline, or those with ocular hypertension who underwent intraocular pressure reduction therapy, and those with a history or suspicion of glaucoma.
  6. Those with any systemic disease are expected to potentially affect the study results. It includes but is not limited to Sjögren syndrome, Stevens-Johnson syndrome, rheumatoid arthritis, , systemic lupus erythematosus, scleroderma, sarcoidosis, herpes, acne, rosacea, etc.
  7. Those who cannot stop using any ocular medication or treatment during the clinical trial.
  8. Those with recent history (e.g., hepatic, renal impairment) within 6 months prior to screening or current severe, unstable, or uncontrolled cardiovascular, pulmonary, hepatic, renal, , and other relevant systemic diseases (e.g., severe , arrhythmia, significant heart failure, uncontrolled hypertension, type 2 diabetes mellitus), as assessed by the investigator.
  9. Those on a chronic, systemic medication regimen used for less than 1 month at screening and baseline or with dose changed within 1 month (including initiation of new medication and discontinuation).
  10. Those who have used any prohibited medications (topical ocular, systemic, and/or injectable medications) during the specified period prior to screening. These medications are also prohibited during the study. However, if a subject has a prohibited medication at screening, it needs to be stopped and washed out according to the specified below, which can be included in the wash-out period. The minimum reasonable washout period for prohibited medications is as follows:

    • Systemic and local and immunotherapy (such as cyclosporine eye drops, tacrolimus eye drops, etc.): 60 days;
    • (any route): 14 days;
    • Systemic or ocular topical mast cell stabilizers, antihistamines, antihistamines/mast cell stabilizer combination, vasoconstrictors, monoamine oxidase inhibitors: 7 days;
    • Other topical ophthalmic preparations (including artificial tears): 3 days;
    • Medications known to cause ocular dryness (e.g., anticholinergics, serotonin reuptake inhibitors, beta-blockers, diuretics, etc.): 14 days.

    Note: Non-periocular, low-potency, over-the-counter corticosteroid topical skin creams are allowed for use in the study (e.g., hydrocortisone butyrate cream/ointment).

  11. Those who wore corneal contact lenses within 7 days prior to screening or required them during the study.
  12. Those who underwent meibomian gland massage or moist chamber therapy within 7 days prior to screening, or non-drug therapies for dry eye such as intense pulsed light therapy, thermal pulsation therapy, etc., within the previous 6 months before screening.
  13. Those who previously underwent dry eye surgery such as tear duct embolization (current tear duct embolization status or punctal plug use in the past 6 months) or amniotic membrane transplantation.
  14. Those who underwent ocular surface surgery (e.g., LASIK excimer laser in situ keratomileusis) within 12 months prior to screening or intraocular surgery within 6 months prior to screening in either eye, as determined by the subject's medical history and/or examination, or anticipated ocular surgery during the study.
  15. Those who use other products or devices within 3 months prior to screening or concurrently during the study.
  16. Non-compliance with drug administration (\< 80% or > 120%) during the introduction period.
  17. Females of who are currently pregnant, or have a positive pregnancy test result, or plan to get pregnant during the study, or are currently breastfeeding, or do not agree to use appropriate methods to avoid pregnancy during the study period up to 1 month after the last dose of study drug.
  18. Males who do not agree to use one or more acceptable effective contraception methods during the study period up to 1 month after the last dose of study drug.
  19. Any condition or situation that, in the opinion of the investigator, may pose a safety risk to the subject in the trial or may interfere with the conduct of the study, or the investigator believes that the subject may not be able to complete or comply with the requirements of the study (due to administrative reasons or otherwise).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
842 participants (estimated)

Study arms

  • Experimental
    OT202 conc. 1% group

    Administered three times daily, with 1-2 drops each time, instilled into the conjunctival sac.

    Drug: OT202 conc 1%

  • Experimental
    Placebo group

    Administered three times daily, with 1-2 drops each time, instilled into the conjunctival sac.

    Drug: Placebo

Interventions

  • DrugOT202 conc 1%

    Apply 1-2 drops of OT202 1% solution into the conjunctival sac. three times daily

  • DrugPlacebo

    Apply 1-2 drops of placebo solution into the conjunctival sac. three times daily

06

What researchers measure

Primary outcomes

  1. Total Corneal Fluorescein Staining (TCSS) score

    Compare the difference of changes in TCSS relative to baseline of two study groups on day 56.

    Time frame: Day 56

  2. Total visual analogue scale (VAS)-eye dryness score (EDS) score

    Compare the between-group differences in the change from baseline for total VAS-EDS score on Day 56.

    Time frame: Day 56

Secondary outcomes

  1. Symptom assessment in dry eye (SANDE) scores

    Compare the between-group differences in the change from baseline for SANDE scores on Day 56

    Time frame: Day 56

  2. Ocular surface disease index (OSDI) scores

    Compare the between-group differences in the change from baseline for OSDI scores on Day 56

    Time frame: Day 56

  3. Corneal staining scores

    Compare the between-group differences in the change from baseline for corneal staining scores (including individual corneal zone scores and total corneal staining scores at Visits 3 and 4) at Visit 3 (Day 14), Visit 4 (Day 28), and Visit 5 (Day 56).

    Time frame: Day 14\Day 28\Day 56

  4. Tear film break-up time (TFBUT)

    Compare the between-group differences in the change from baseline for TFBUT at Visit 3 (Day 14), Visit 4 (Day 28), and Visit 5 (Day 56).

    Time frame: Day 14\Day 28\Day 56

  5. Schirmer I test

    Compare the between-group differences in the change from baseline for Schirmer I test at Visit 3 (Day 14), Visit 4 (Day 28), and Visit 5 (Day 56).

    Time frame: Day 14\Day 28\Day 56

07

Study locations

1 of 49 sites recruiting
  • The First Affiliated Hospital of Bengbu Medical University
    Bengbu, Anhui 233004, China
    Not yet recruiting
    • Ziqing Gao · Contact
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230601, China
    Not yet recruiting
    • Liming Tao · Contact
  • Peking University People's Hospital
    Beijing, Beijing Municipality 100044, China
    Not yet recruiting
    • Mingwei Zhao · Contact
  • Peking Union Medical College Hospital
    Beijing, Beijing Municipality 100730, China
    Not yet recruiting
    • Di Chen · Contact
  • Chongqing Aier Eye Hospital
    Chongqing, Chongqing Municipality 400020, China
    Not yet recruiting
    • Yi Ren · Contact
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
    Not yet recruiting
    • Limin Chen · Contact
  • Xiamen Eye Center Affiliated to Xiamen University
    Xiamen, Fujian 361003, China
    Not yet recruiting
    • Huping Wu · Contact
  • Zhongshan Ophthalmic Center, Sun Yat-sen University
    Guangzhou, Guangdong 510060 / 510623, China
    Not yet recruiting
    • Saiqun Li · Contact
  • Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong
    Shantou, Guangdong 515041, China
    Not yet recruiting
    • Di Ma · Contact
  • Shenzhen Eye Hospital
    Shenzhen, Guangdong 518040, China
    Not yet recruiting
    • Ping Guo · Contact
  • The People's Hospital of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530021, China
    Not yet recruiting
    • Qi Chen · Contact
  • The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
    Guiyang, Guizhou 550001, China
    Not yet recruiting
    • Xianfeng Yao · Contact
  • Hainan Eye Hospital of Zhongshan Ophthalmic Center, Sun Yat-sen University
    Haikou, Hainan 570102, China
    Not yet recruiting
    • Haisheng Zheng · Contact
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 50000, China
    Not yet recruiting
    • Danyan Liu · Contact
  • Harbin No.242 Hospital
    Harbin, Heilongjiang 150066, China
    Not yet recruiting
    • Xiaomei Gou · Contact
  • The 2nd Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150086, China
    Not yet recruiting
    • Dawei Sun · Contact
  • Zhengzhou Second Hospital
    Zhengzhou, Henan 450015, China
    Not yet recruiting
    • Qian Wang · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Not yet recruiting
    • Guangming Wan · Contact
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Not yet recruiting
    • Mingchang Zhang · Contact
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
    Not yet recruiting
    • Hongmei Zheng · Contact
  • Zhongnan Hospital of Wuhan University
    Wuhan, Hubei 430071, China
    Not yet recruiting
    • Min Ke · Contact
  • Xiangya Hospital of Central South University
    Changsha, Hunan 410008, China
    Not yet recruiting
    • Hua Wang · Contact
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
    Not yet recruiting
    • Zhihong Deng · Contact
  • Changsha Aier Eye Hospital
    Changsha, Hunan 410015, China
    Not yet recruiting
    • Kuanshu Li · Contact
  • Changzhou Third People's Hospital
    Changzhou, Jiangsu 213001, China
    Not yet recruiting
    • Songtao Yuan · Contact
  • Nanjing Medical University Eye Hospital
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
    • Jinsong Xue · Contact
  • The First People's Hospital of Xuzhou
    Xuzhou, Jiangsu 221000, China
    Not yet recruiting
    • Suyan Li · Contact
  • Northern Jiangsu People's Hospital
    Yangzhou, Jiangsu 225001, China
    Not yet recruiting
    • Fen Zhou · Contact
  • Yanbian University Hospital
    Yanji, Jilin 133000, China
    Not yet recruiting
    • Renzhe Cui · Contact
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
    Not yet recruiting
    • Xiang Ma · Contact
  • The First Affiliated Hospital of China Medical University
    Shenyang, Liaoning 110001, China
    Not yet recruiting
    • Han Zhang · Contact
  • The Fourth People's Hospital of Shenyang
    Shenyang, Liaoning 110031, China
    Not yet recruiting
    • Tongtong Niu · Contact
  • People's Hospital of Ningxia Hui Autonomous Region
    Yinchuan, Ningxia 750002, China
    Not yet recruiting
    • Yan Zhu · Contact
  • Xi'an NO.1 Hospital
    Xi'an, Shaanxi 710002, China
    Not yet recruiting
    • Yan Cheng · Contact
  • Xi'an People's Hospital (Xi'an Fourth Hospital
    Xi'an, Shaanxi 710004, China
    Not yet recruiting
    • Yong Li · Contact
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710061, China
    Not yet recruiting
    • Li Li · Contact
  • Qilu Hospital of Shandong University
    Jinan, Shandong 250012, China
    Not yet recruiting
    • Jianqiao Li · Contact
  • Qingdao Eye Hospital of Shandong First Medical University
    Qingdao, Shandong 266011, China
    Not yet recruiting
    • Yanling Dong · Contact
  • Weifang Eye Hospital
    Weifang, Shandong 261041, China
    Not yet recruiting
    • Jibing Wang · Contact
  • Shanghai Eye Disease Prevention and Treatment Center
    Shanghai, Shanghai Municipality 200040, China
    Not yet recruiting
    • Jiannan Huang · Contact
  • Tongren Hospital Shanghai Jiao Tong University School Of Medicine
    Shanghai, Shanghai Municipality 200336, China
    Not yet recruiting
    • Qinghua Qiu · Contact
  • Shanxi Eye Hospital
    Taiyuan, Shanxi 30002, China
    Not yet recruiting
    • Xiaofen Zheng · Contact
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
    Not yet recruiting
    • Jing Tang · Contact
  • Tianjin Eye Hospital
    Tianjin, Tianjin Municipality 300020, China
    Not yet recruiting
    • Luxia Chen · Contact
  • Tianjin Medical University Eye Hospital
    Tianjin, Tianjin Municipality 300384, China
    Not yet recruiting
    • Hui Liu · Contact
  • Affiliated Hospital of Yunnan University (The Second People's Hospital of Yunnan Province / Yunnan Eye Hospital)
    Kunming, Yunnan 650021, China
    Not yet recruiting
    • Hai Liu · Contact
  • The Second Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
    Not yet recruiting
    • Xiuming Jin · Contact
  • Ningbo Eye Hospital
    Ningbo, Zhejiang 315040, China
    Not yet recruiting
    • Feng Wen · Contact
  • Eye Hospital, WMU
    Wenzhou, Zhejiang 325027, China
    Recruiting
    • Jia Qu · Contact
    • Wei Chen · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jan 2029, 29 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's planned 29 months is above that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Jul 31, 2026
StartActual
Aug 25, 2026
Primary completionEst.
Jan 2029
CompletionEst.
May 2029
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 15, 2026
Sites
49 sites changed recruiting status (48 now not yet recruiting, 1 now recruiting)
Show 49 sites
  • The First Affiliated Hospital of Bengbu Medical University · Bengbu, Chinano status→Not yet recruiting
  • The Second Affiliated Hospital of Anhui Medical University · Hefei, Chinano status→Not yet recruiting
  • Peking University People's Hospital · Beijing, Chinano status→Not yet recruiting
  • Peking Union Medical College Hospital · Beijing, Chinano status→Not yet recruiting
  • Chongqing Aier Eye Hospital · Chongqing, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Fujian Medical University · Fuzhou, Chinano status→Not yet recruiting
  • Xiamen Eye Center Affiliated to Xiamen University · Xiamen, Chinano status→Not yet recruiting
  • Zhongshan Ophthalmic Center, Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
  • Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong · Shantou, Chinano status→Not yet recruiting
  • Shenzhen Eye Hospital · Shenzhen, Chinano status→Not yet recruiting
  • The People's Hospital of Guangxi Zhuang Autonomous Region · Nanning, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine · Guiyang, Chinano status→Not yet recruiting
  • Hainan Eye Hospital of Zhongshan Ophthalmic Center, Sun Yat-sen University · Haikou, Chinano status→Not yet recruiting
  • The Second Hospital of Hebei Medical University · Shijiazhuang, Chinano status→Not yet recruiting
  • Harbin No.242 Hospital · Harbin, Chinano status→Not yet recruiting
  • The 2nd Affiliated Hospital of Harbin Medical University · Harbin, Chinano status→Not yet recruiting
  • Zhengzhou Second Hospital · Zhengzhou, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
  • Renmin Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
  • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
  • Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
  • The Third Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
  • Changsha Aier Eye Hospital · Changsha, Chinano status→Not yet recruiting
  • Changzhou Third People's Hospital · Changzhou, Chinano status→Not yet recruiting
  • Nanjing Medical University Eye Hospital · Nanjing, Chinano status→Not yet recruiting
  • The First People's Hospital of Xuzhou · Xuzhou, Chinano status→Not yet recruiting
  • Northern Jiangsu People's Hospital · Yangzhou, Chinano status→Not yet recruiting
  • Yanbian University Hospital · Yanji, Chinano status→Not yet recruiting
  • The First Affiliated Hospital of Dalian Medical University · Dalian, Chinano status→Not yet recruiting
  • …and 19 more on the registry record
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Recruiting
    49 sites changed recruiting status (48 now not yet recruiting, 1 now recruiting)
    Show 49 sites
    • The First Affiliated Hospital of Bengbu Medical University · Bengbu, Chinano status→Not yet recruiting
    • The Second Affiliated Hospital of Anhui Medical University · Hefei, Chinano status→Not yet recruiting
    • Peking University People's Hospital · Beijing, Chinano status→Not yet recruiting
    • Peking Union Medical College Hospital · Beijing, Chinano status→Not yet recruiting
    • Chongqing Aier Eye Hospital · Chongqing, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Fujian Medical University · Fuzhou, Chinano status→Not yet recruiting
    • Xiamen Eye Center Affiliated to Xiamen University · Xiamen, Chinano status→Not yet recruiting
    • Zhongshan Ophthalmic Center, Sun Yat-sen University · Guangzhou, Chinano status→Not yet recruiting
    • Shantou International Eye Center of Shantou University and The Chinese University of Hong Kong · Shantou, Chinano status→Not yet recruiting
    • Shenzhen Eye Hospital · Shenzhen, Chinano status→Not yet recruiting
    • The People's Hospital of Guangxi Zhuang Autonomous Region · Nanning, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine · Guiyang, Chinano status→Not yet recruiting
    • Hainan Eye Hospital of Zhongshan Ophthalmic Center, Sun Yat-sen University · Haikou, Chinano status→Not yet recruiting
    • The Second Hospital of Hebei Medical University · Shijiazhuang, Chinano status→Not yet recruiting
    • Harbin No.242 Hospital · Harbin, Chinano status→Not yet recruiting
    • The 2nd Affiliated Hospital of Harbin Medical University · Harbin, Chinano status→Not yet recruiting
    • Zhengzhou Second Hospital · Zhengzhou, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Chinano status→Not yet recruiting
    • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Chinano status→Not yet recruiting
    • Renmin Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
    • Zhongnan Hospital of Wuhan University · Wuhan, Chinano status→Not yet recruiting
    • Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
    • The Third Xiangya Hospital of Central South University · Changsha, Chinano status→Not yet recruiting
    • Changsha Aier Eye Hospital · Changsha, Chinano status→Not yet recruiting
    • Changzhou Third People's Hospital · Changzhou, Chinano status→Not yet recruiting
    • Nanjing Medical University Eye Hospital · Nanjing, Chinano status→Not yet recruiting
    • The First People's Hospital of Xuzhou · Xuzhou, Chinano status→Not yet recruiting
    • Northern Jiangsu People's Hospital · Yangzhou, Chinano status→Not yet recruiting
    • Yanbian University Hospital · Yanji, Chinano status→Not yet recruiting
    • The First Affiliated Hospital of Dalian Medical University · Dalian, Chinano status→Not yet recruiting
    • …and 19 more on the registry record
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07740564
Lead sponsor
Ocumension Therapeutics (Suzhou) Co., Ltd
Responsible party
Sponsor
First posted
Jul 31, 2026
Start date
Aug 25, 2026
Primary completion
Jan 2029 (estimated)
Completion
May 2029 (estimated)
Last update
Oct 15, 2026

Study contacts

Wei Chen
Contact
chenwei@eye.ac.cn
0577-88075582
Jia Qu
Contact
jia.qu@163.com
0577-88068888
Wei Chen
principal investigator · Eye Hospital, WMU
Jialu Xia
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion